DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds, each clinically approved by major regulators such as the FDA, EMA, and PMDA (ApexBio). These compounds span a range of mechanisms, including enzyme inhibitors, receptor modulators, and signal pathway regulators. The library is optimized for high-throughput and high-content screening, advancing drug repositioning and novel target discovery (Sigurdardóttir et al., 2024). Its format—pre-dissolved 10 mM DMSO solutions—ensures compatibility with automated screening workflows. Recent studies confirm the library's utility in identifying cell-permeable inhibitors, including those overlooked by standard in vitro assays (DOI).

Biological Rationale

Drug repurposing accelerates therapeutic development by leveraging clinically approved molecules (Sigurdardóttir et al., 2024). FDA-approved compound collections, such as the DiscoveryProbe™ FDA-approved Drug Library, provide researchers with a wide spectrum of pharmacologically active agents that have established safety profiles. This approach reduces the translational gap and enables direct exploration of human-relevant pharmacology (Related insight). The ability to screen bioactive molecules with known ADMET (absorption, distribution, metabolism, excretion, toxicity) characteristics streamlines hit validation and clinical pathway planning.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library comprises compounds with diverse mechanisms, including:

• Receptor agonists and antagonists: Modulate GPCRs, nuclear receptors, and ion channels (e.g., metformin, doxorubicin).
• Enzyme inhibitors: Target kinases, proteases, and metabolic enzymes (e.g., atorvastatin, bortezomib).
• Signal pathway modulators: Affect PI3K/Akt, MAPK, and other signaling cascades.
• Ion channel modulators: Alter calcium, potassium, and sodium flux in disease models.

Each compound's mechanism is well-characterized in regulatory dossiers and peer-reviewed literature (Product page).

Evidence & Benchmarks

• Screening of ~2,500 small molecules, including FDA-approved drugs, in a yeast-based positive selection system identified eight SARS-CoV-2 MPro inhibitors, five of which are proteasome inhibitors (Sigurdardóttir et al., 2024).
• Boron-containing drugs (bortezomib, delanzomib, ixazomib) were confirmed as MPro inhibitors under non-standard buffer conditions, highlighting the importance of cellular assay context (DOI).
• The DiscoveryProbe™ FDA-approved Drug Library supports high-throughput screening and target identification in both cancer and neurodegenerative disease models (HDAC4 analysis).
• Consistent compound stability (12 months at -20°C, 24 months at -80°C) allows reliable, long-term HTS campaigns (ApexBio).
• Cellular screening platforms can identify membrane-permeable, biostable compounds that in vitro enzymatic assays may miss (Sigurdardóttir et al., 2024).

Applications, Limits & Misconceptions

This library is widely applied in:

• Cancer research drug screening: Enables chemosensitization studies and discovery of novel resistance modulators.
• Neurodegenerative disease drug discovery: Facilitates identification of neuroprotective agents and pathway modulators.
• Signal pathway regulation: Supports network analysis of complex signaling interactions.
• Enzyme inhibitor screening: Allows for rapid profiling of kinase, protease, and metabolic enzyme inhibitors.
• Drug repositioning screening: Expedites the identification of new indications for existing drugs.

Common Pitfalls or Misconceptions

• The library does not include investigational or preclinical-only compounds—only those with regulatory approval or pharmacopeial status.
• Standard in vitro enzymatic assays may not detect all active compounds, especially those requiring cellular context or non-standard buffer conditions (DOI).
• Compounds with known high toxicity or instability under screening conditions may yield false negatives in some cellular assays.
• The library is not a substitute for target-specific, custom compound collections but serves as a broad, hypothesis-generating resource.
• Results from HTS require secondary validation in disease-relevant models; hits are not automatically translatable to clinical efficacy.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is supplied as 10 mM DMSO solutions, compatible with 96-well and deep-well plate formats, and 2D-barcoded tubes. Compounds remain stable for 12 months at -20°C and up to 24 months at -80°C. Shipping options include blue ice or ambient temperature, with evaluation samples always shipped on blue ice (ApexBio).

Integration into automated HTS and HCS platforms is straightforward. Barcode tracking supports sample provenance. Researchers should verify compound integrity upon receipt and before screening. For screens requiring cell-permeability or specific buffer conditions (e.g., for boron-containing proteasome inhibitors), protocol adjustments may be needed (Sigurdardóttir et al., 2024).

For further methodology and strategic guidance on integrating FDA-approved compound libraries in translational pipelines, see "Next-Generation High-Throughput Screening: Mechanistic Insights for Translational Impact" (precisionfda.org), which details advances that this article extends by focusing on regulatory diversity and workflow stability.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library offers a robust, regulatory-anchored resource for high-throughput drug screening and pharmacological target identification. Its breadth, stability, and format suitability empower disease modelers and translational researchers to accelerate drug repurposing and mechanistic discovery. As demonstrated in recent yeast-based protease inhibitor screens, the library's inclusion of cell-permeable, clinically validated compounds enables detection of functional hits missed by conventional in vitro assays (DOI). Future directions include further integration with machine learning-driven screening and expansion into rare disease applications. For more detailed mechanistic use cases, our discussion clarifies and updates insights from earlier reports (moleculeprobe.com), particularly regarding selective pathway modulation in oncology and neurodegeneration.